Recruiting

Observational Study

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT06907797

Conditions

Acute Leukemia

Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TRIAL Web-Based Application

Study Details

Brief summary:

This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

Conditions

Acute Leukemia

Leukemia

Study ID

NCT06907797

Start date

Apr 1, 2025

Status verified date

Sep, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

May 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18 or older
  • English speaking
  • Ability to understand and willingness to sign written informed consent
  • Clinical suspicion of acute leukemia
  • Admitted to DFCI-affiliated inpatient unit

Exclusion Criteria:

  • Cognitive impairment rendering the individual unable to participate in beta testing

  • This will be assessed by focused chart review and consultation with the patients' inpatient care team.
  • The following populations will be excluded: adults unable to consent, individuals who are not yet adults (infants, children, teenagers <18 years old), prisoners.
  • Inability to participate in in-person application testing.
  • Patients who participated in alpha-testing through protocol 23-404 (Appendix A)

Study Design

Enrollment

75 participants

Anticipated

Intervention Model

Single group

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: TRIAL Web-Based Application

Enrolled participants will complete:

  • Baseline visit and questionnaires
  • Access to web application over the course of 14 days.
  • End of study questionnaires
  • 12 participants will take part in semi-structured interviews with study staff which will be audio recorded.

Interventions

TRIAL Web-Based Application

A web-based application that provides disease and trial education and access to resources provided by the Leukemia and Lymphoma Society (LLS). iPads will be provided to participants for 14 days.

Primary outcome measure

  • Post-Test Completion Rate [ Time Frame: Day 14 or date of discharge ]
  • System Usability Scale (SUS) Score [ Time Frame: Day 14 or date of discharge ]
  • Percentage of Participants Scoring ≥68 on SUS [ Time Frame: approximately 12 months (based on total accrual duration) ]

Central Contacts and Locations

Central contacts

Andrew Hantel, MD

617-582-9394Andrew_hantel@dfci.harvard.edu

Oldy S Bejarano, MPH

857-215-2365oldy_bejarano@dfci.harvard.edu

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Andrew Hantel, MD

617-582-9394Andrew_Hantel@dfci.harvard.edu

Principal Investigator:

Andrew Hantel, MD

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • Acute Leukemia
  • Leukemia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-09-09.